Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 427 in Relapsed/Refractory Acute Myeloid Leukemia
NCT03541369Phase 1Terminated
- Sponsor
- Amgen
- Start
- Sep 2018
- Primary completion
- Feb 2023
- Modality
- Bispecific Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of FLT3-directed BiTE molecule in acute myeloid leukemia (AML), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-emergent Adverse Events. Started Sep 2018; status: terminated.
02
Drugs
FLT3-directed BiTE molecule
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03541369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541369.